--- type: "Topics" locale: "zh-HK" url: "https://longbridge.com/zh-HK/topics/43154760.md" description: "๐Ÿ“ข ๐—๐—จ๐—ฆ๐—ง ๐—œ๐—ก: $็ฆฎไพ†(LLY.US) Eli Lilly's Olomorasib Receives FDA Breakthrough Therapy Designation for Pancreatic Cancer๐Ÿ‘‰ ๐—ž๐—ฒ๐˜† ๐—›๐—ถ๐—ด๐—ต๐—น๐—ถ๐—ด๐—ต๐˜๐˜€:โžค ๐—˜๐—น๐—ถ ๐—Ÿ๐—ถ๐—น๐—น๐˜†'s ๐—ผ๐—น๐—ผ๐—บ๐—ผ๐—ฟ๐—ฎ๐˜€๐—ถ๐—ฏ receives ๐—™๐——๐—” ๐—•๐—ฟ๐—ฒ๐—ฎ๐—ธ๐˜๐—ต๐—ฟ๐—ผ๐˜‚๐—ด๐—ต ๐—ง๐—ต๐—ฒ๐—ฟ๐—ฎ๐—ฝ๐˜† designation.โžค Designation covers previously treated ๐—ž๐—ฅ๐—”๐—ฆ ๐—š๐Ÿญ๐Ÿฎ๐—–-mutant advanced pancreatic cancer.โžค Olomorasib is a next-generation ๐—ž๐—ฅ๐—”๐—ฆ ๐—š๐Ÿญ๐Ÿฎ๐—– inhibitor under investigation.โžค FDA designation is intended to accelerate drug development and review.โžค No approved targeted therapies currently exist for ๐—ž๐—ฅ๐—”๐—ฆ ๐—š๐Ÿญ๐Ÿฎ๐—–-mutant pancreatic cancer.โžค Decision is based on preliminary ๐—ฃ๐—ต๐—ฎ๐˜€๐—ฒ ๐Ÿญ/๐Ÿฎ ๐—Ÿ๐—ข๐—ซ๐—ข-๐—ฅ๐—”๐—ฆ-๐Ÿฎ๐Ÿฌ๐Ÿฌ๐Ÿฌ๐Ÿญ trial results.โžค Olomorasib previously received Breakthrough Therapy designation in ๐—ž๐—ฅ๐—”๐—ฆ ๐—š๐Ÿญ๐Ÿฎ๐—–-mutant NSCLC.โžค Lilly continues evaluating olomorasib across multiple ๐—ž๐—ฅ๐—”๐—ฆ ๐—š๐Ÿญ๐Ÿฎ๐—–-driven cancers.๐Ÿ‘‰ ๐—ช๐—ต๐˜† ๐—ง๐—ต๐—ถ๐˜€ ๐— ๐—ฎ๐˜๐˜๐—ฒ๐—ฟ๐˜€:โžค FDA designation may accelerate regulatory review and clinical development.โžค Addresses a major unmet need in a cancer with limited treatment options.โžค Expands Lilly's oncology pipeline in precision cancer therapies.โžค Reinforces momentum for ๐—ž๐—ฅ๐—”๐—ฆ-targeted cancer drug development.๐Ÿ‘‰ ๐—˜๐˜…๐—ฝ๐—ฒ๐—ฟ๐˜ ๐—ฆ๐˜๐—ฎ๐˜๐—ฒ๐—บ๐—ฒ๐—ป๐˜:๐—๐—ฎ๐—ฐ๐—ผ๐—ฏ ๐—ฉ๐—ฎ๐—ป ๐—ก๐—ฎ๐—ฎ๐—ฟ๐—ฑ๐—ฒ๐—ป, Executive Vice President and President of Lilly Oncology:"Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses. This Breakthrough Therapy designation reflects the early potential we're seeing with olomorasib in this setting and the critical need for new treatment options. With now two Breakthrough Therapy designations across pancreatic and lung cancers, olomorasib continues to demonstrate broad potential clinical evidence across KRAS G12C-driven tumors and reflects our commitment to bringing meaningful new treatment options to patients living with these cancers."" datetime: "2026-08-03T11:46:43.000Z" locales: - [en](https://longbridge.com/en/topics/43154760.md) - [zh-CN](https://longbridge.com/zh-CN/topics/43154760.md) - [zh-HK](https://longbridge.com/zh-HK/topics/43154760.md) author: "[Hardik Shah](https://longbridge.com/zh-HK/profiles/27423834.md)" --- # ๐Ÿ“ข ๐—๐—จ๐—ฆ๐—ง ๐—œ๐—ก: $็ฆฎไพ†(LLY.US) Eli Lilly's Olomorasโ€ฆ ### ็›ธ้—œ่‚ก็ฅจ - [LLY.US](https://longbridge.com/zh-HK/quote/LLY.US.md)